Core Points - The CSI 1000 Quality Index has shown a decline of 8.35% over the past month, an increase of 1.30% over the last three months, and a year-to-date decrease of 1.62% [1] - The index is composed of 100 listed companies selected from the CSI 1000 Index based on their operational stability, profitability, and quality metrics [1] - The top ten weighted companies in the CSI 1000 Quality Index include Yuxin Technology (3.39%), Dataport (3.21%), Tonghua Jinma (3.11%), and others [1] Industry Composition - The industry distribution of the CSI 1000 Quality Index shows that the healthcare sector accounts for 24.45%, industrials for 18.35%, and information technology for 14.63% [2] - Other sectors include consumer discretionary (9.77%), financials (9.69%), communication services (8.13%), and materials (5.64%) [2] - The index undergoes semi-annual adjustments, with changes implemented on the next trading day following the second Friday of June and December [2]

Group 1 - As of April 18, the total market financing balance is 1.79 trillion yuan, a decrease of 6.28 billion yuan from the previous trading day, marking three consecutive days of decline [1] - The financing balance for the Shanghai Stock Exchange is 913.65 billion yuan, down by 3.34 billion yuan; for the Shenzhen Stock Exchange, it is 873.79 billion yuan, down by 2.93 billion yuan; and for the Beijing Stock Exchange, it is 5.28 billion yuan, down by 19.61 million yuan [1] - On April 18, a total of 1,349 stocks received net financing purchases, with 158 stocks having net purchases exceeding 10 million yuan, and 10 stocks with net purchases over 50 million yuan [1] Group 2 - The top net financing purchase on April 18 was for Tuowei Information, with a net purchase amount of 168 million yuan, followed by Hanwujing and Wo Ai Wo Jia with net purchases of 156 million yuan and 76.97 million yuan, respectively [1] - In terms of industry, the stocks with net purchases exceeding 50 million yuan are concentrated in the computer, pharmaceutical, and non-ferrous metal sectors, with two stocks from each industry on the list [1] - Among the stocks with significant net purchases, 8 are from the main board, 1 from the ChiNext board, and 1 from the Sci-Tech Innovation board [1] Group 3 - The average ratio of financing balance to circulating market value for stocks with large net purchases is 3.65%, with ZTE Communications having the highest ratio at 5.88% [2] - Other stocks with high financing balance ratios include Tonghua Golden Horse, Wo Ai Wo Jia, and Tuowei Information, with ratios of 5.33%, 5.32%, and 5.01%, respectively [2] - The financing net purchase rankings for April 18 show that Tuowei Information increased by 3.17%, while Hanwujing decreased by 1.10% [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000766 证券简称：通化金马 公告编号：2025-23 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第一季度报告是否经审计 □是 √否 一、主要财务数据 单位：元 ■ 其他符合非经常性损益定义的损益项目的具体情况 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 ■ （二） 非经常性损益项目和金额 √适用 □不适用 ■ 二、股东信息 （一） 普通股股东总数和表决权恢复的优先股股东数量及前十名股东持股情况表 ■ □适用 √不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》中列举的非经常性损益项目界 定为 ...

前十大流通股东累计持有： 38297.27万股，累计占流通股比： 39.65%，较上期变化： 678.91万股。 | 名称 | 持有数量(万股) | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 于兰军 | 19000.00 | 19.67 | 不变 | | 李佳 | 4099.99 | 4.24 | 不变 | | 孙常好 | 3899.99 | 4.04 | 不变 | | 上海木恺贸易有限公司 | 2865.20 | 2.97 | 386.20 | | 唐骁妮 | 2000.00 | 2.07 | 不变 | | 通化市永信投资有限责任公司 | 2000.00 | 2.07 | 不变 | | 田建峰 | 1768.00 | 1.83 | 259.58 | | 上海银行（601229）股份有限公司-银华中证创新药产业交 | | | | | 易型开放式指数证券投资基金 | 1210.32 | 1.25 | 新进 | | 大连喜来商贸有限公司 | 730.00 | 0.76 | 不变 | | 招商银行股份有限公司-南方中证1000交易型 ...

证券代码：000766 证券简称：通化金马 公告编号：2025-22 通化金马药业集团股份有限公司 第十一届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 会议以 3 票赞同，0 票反对，0 票弃权，审议通过了公司 2025 年第一季度报 告。 三、备查文件 2. 2025 年 4 月 18 日上午 11 时以现场和通讯方式召开。 3.会议应到监事 3 人，实到监事 3 人。 4.会议由监事会主席许长有主持。 5.本次监事会会议的召开符合有关法律、行政法规、部门规章、规范性文件 和公司章程的规定。 二、监事会会议审议情况 审议公司 2025 年第一季度报告 监事会的专项审核意见：经审核，监事会认为董事会编制和审议公司 2025 年第一季度报告的程序符合法律、行政法规及中国证监会的规定，报告内容真实、 准确、完整地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或 者重大遗漏。 公司 2025 年第一季度报告同日披露于巨潮资讯网。 1.通化金马药业集团股份有限公司第十一届监事会第九次会议通知于 2025 ...

通化金马药业集团股份有限公司 第十一届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1.通化金马药业集团股份有限公司第十一届董事会第九次会议通知于 2025 年 4 月 8 日以微信和电子邮件形式送达全体董事。 2. 2025 年 4 月 18 日上午 9 时 30 分以现场和通讯方式召开。 3.会议应到董事 9 人，实到董事 9 人。 证券代码：000766 证券简称：通化金马 公告编号：2025-21 5.本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性文件 和公司章程的规定。 二、董事会会议审议情况 审议公司 2025 年第一季度报告 公司 2025 年第一季度报告同日披露于巨潮资讯网。 本议案已经董事会审计委员会全票审议通过。 会议以 9 票赞同，0 票反对，0 票弃权，审议通过了公司 2025 年第一季度报 告。 三、备查文件 经与会董事签字并加盖董事会印章的董事会决议。 通化金马药业集团股份有限公司董事会 2025 年 4 月 18 日 4.会议由董事长张玉富先生主持。监事会成员及部分 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 299,282,436.73, representing a 1.25% increase compared to CNY 295,573,016.13 in the same period last year[4] - Net profit attributable to shareholders increased by 26.09% to CNY 11,582,762.07 from CNY 9,186,280.68 year-on-year[4] - The basic and diluted earnings per share rose by 26.32% to CNY 0.0120 from CNY 0.0095 in the same quarter last year[4] - The company's net profit for the current period is 11,569,989.81, an increase of 26.2% compared to 9,165,796.92 in the previous period[20] - Operating profit reached 14,335,267.74, up from 10,878,079.74, reflecting a growth of 31.3%[20] - The total profit for the current period is 14,416,192.63, compared to 10,864,139.42 in the previous period, showing an increase of 32.5%[20] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to CNY 41,800,049.38, a 473.28% increase from a negative CNY 11,198,052.98 in the previous year[4] - Cash and cash equivalents at the end of the period amounted to ¥332,013,374.68, up from ¥274,177,490.80 at the beginning of the period, showing a growth of about 21.0%[14] - Cash and cash equivalents at the end of the period totaled 331,618,632.84, an increase from 240,560,041.23 in the previous period, reflecting a growth of 37.9%[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,523,874,132.66, a 0.90% increase from CNY 4,483,618,602.64 at the end of the previous year[4] - Total current assets rose to ¥1,264,262,686.64 from ¥1,209,964,232.75, indicating an increase of about 4.5%[15] - Total liabilities increased to ¥2,256,901,221.08 from ¥2,228,215,680.87, reflecting a growth of approximately 1.3%[16] - Non-current assets decreased slightly to ¥3,259,611,446.02 from ¥3,273,654,369.89, indicating a decline of approximately 0.43%[15] Research and Development - The company's R&D expenses increased by 36.07% to CNY 10,687,229.31 compared to CNY 7,854,193.40 in the same period last year[8] - Research and development expenses increased to 10,687,229.31, up from 7,854,193.40, representing a rise of 35.5%[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 37,074[10] - The largest shareholder, Yu Lanjun, holds 19.66% of the shares, amounting to 190,000,000 shares, with 150,000,000 shares pledged[11] Other Income and Expenses - The company reported a decrease of 49.60% in other income, totaling CNY 2,026,653.35 compared to CNY 4,021,420.65 in the previous year[8] - The income tax expense increased by 67.59% to CNY 2,846,202.82 from CNY 1,698,342.50 year-on-year[8] - The company incurred financial expenses of 19,607,550.57, up from 15,278,523.05, which is an increase of 28.5%[20] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[24]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000766 证券简称：通化金马 公告编号：2025-18 一、重要提示 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者 应当到证监会指定媒体仔细阅读年度报告全文。 公司所处行业为医药制造业，主要从事医药产品的研发、生产与销售。公司及子公司产品涵盖抗肿瘤、 微生物、心脑血管、清热解毒、消化系统、骨骼肌肉系统、妇科系统、神经系统等多个领域。母公司的 主导产品主要包括复方嗜酸乳杆菌片、风湿祛痛胶囊、清肝健脾口服液、芩石利咽口服液等。子公司圣 泰生物经营的品种主要集中在骨多肽类、脑保护剂化学药、心脑血管中成药、清热解毒类以及儿童呼吸 系统中成药等五类药品领域，在同类产品零售市场建立了一定的市场地位，主要产品为骨瓜提取物制 剂、转移因子口服溶液、清开灵片及小儿热速清颗粒等。子公司永康制药生产的药品种类主要系中成 药，用于治疗腺体增生、炎性疾病、骨外伤及软组织损伤等相关疾病，主要产品包括小金丸、天然麝香 小金丸、消咳喘胶囊、九味羌活颗粒、熊胆粉、温胃舒片等。子公司源首生物主导产品蜡样芽孢杆菌活 菌胶囊、蜡样芽孢杆菌活 ...

Group 1 - Tonghua Golden Horse (000766.SZ) released its 2024 annual report on April 18, 2025, with 67 institutional investors holding a total of 90.27 million A-shares, accounting for 9.34% of the total share capital [1] - The top ten institutional investors collectively hold 8.90% of the shares, with a decrease of 2.13 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one fund, namely Innovation Drug, increased its holdings by 0.27%, while another fund, Southern CSI 1000 ETF, decreased its holdings by 0.35% [2] - A total of 62 new public funds were disclosed this period, including major funds like Huaxia CSI 1000 ETF and GF Innovation Drug ETF [2] - One foreign institution, Hong Kong Central Clearing Limited, was not disclosed in this period compared to the previous quarter [2]

通化金马药业集团股份有限公司 2024 年度监事会工作报告 2024 年度，公司监事会严格按照《公司法》《公司章程》等规定，对公司依 法运作、财务状况、对外担保、关联交易、内部控制、内幕信息知情人等情况进 行独立、有效的监督检查，主要工作如下： 2024 年通化金马药业集团股份有限公司（以下简称"公司"）监事会根据《公 司法》、《证券法》、《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司 自律监管指引第 1 号——主板上市公司规范运作》等法律法规和《公司章程》 的有关规定，恪尽职守，积极开展相关工作，列席董事会会议和股东大会，并认 真履行对公司规范运作情况和公司董事、高级管理人员履职情况的监督职责，切 实维护公司及全体股东的权益，促进公司规范运作。现将本年度监事会履职情况 报告如下： 一、报告期内，监事会的工作情况 报告期公司监事会共召开了四次会议，具体如下： （一）2024 年 4 月 18 日，公司召开了第十一届监事会第四次会议，审议通 过了《公司 2023 年年度报告及其摘要》、《公司 2023 年度监事会工作报告》、《公 司 2023 年度财务决算报告》、《公司 2023 年度利润分配方案》、 ...